Zodasiran Reduces Triglycerides, ANGPTL3 in Mixed Hyperlipidemia in ARCHES-2 Trial; A phase 2 trial suggests zodasiran significantly reduces triglycerides in patients with mixed hyperlipidemia, showing dose-dependent improvements in lipid profiles.

Media coverage

• Title	Zodasiran Reduces Triglycerides, ANGPTL3 in Mixed Hyperlipidemia in ARCHES-2 Trial; A phase 2 trial suggests zodasiran significantly reduces triglycerides in patients with mixed hyperlipidemia, showing dose-dependent improvements in lipid profiles.
  Media name/outlet	Consultant Live
  Country/Territory	United States
  Date	29/05/24
  Persons	Robert Sidney Rosenson

• Title	Zodasiran Reduces Triglycerides, ANGPTL3 in Mixed Hyperlipidemia in ARCHES-2 Trial
  Media name/outlet	HCP Live
  Country/Territory	United States
  Date	29/05/24
  Persons	Robert Sidney Rosenson